Targeting kidney inflammation as a new therapy for primary hyperoxaluria?

Area of Science:

• Nephrology
• Metabolic Disorders
• Immunology

Background:

• Primary hyperoxalurias (PHs) are genetic disorders of glyoxylate metabolism leading to excessive oxalate production.
• This results in calcium-oxalate crystal deposition in kidneys, causing progressive renal dysfunction and potential end-stage renal disease (ESRD).
• PH Type 1, caused by AGXT mutations, is the most severe form, often necessitating combined liver-kidney transplantation for ESRD patients.

Purpose of the Study:

• To review the pathogenesis of primary hyperoxalurias.
• To summarize current knowledge on calcium-oxalate-mediated inflammation in PH models.
• To highlight the potential of targeting the NLRP3 inflammasome as a therapeutic strategy.

Main Methods:

• Review of existing literature on primary hyperoxalurias and related animal models.
• Analysis of the role of NACHT, LRR and PYD domains-containing protein 3 (NALP3)-dependent inflammasome activation in oxalate nephropathy.
• Exploration of therapeutic implications of targeting inflammatory pathways.

Main Results:

• Calcium-oxalate crystal accumulation triggers a pro-inflammatory environment via NALP3 inflammasome activation in renal immune cells.
• This chronic inflammation promotes renal fibrogenesis, leading to impaired kidney function.
• Experimental models demonstrate that targeting inflammation can mitigate oxalate-induced kidney damage.

Conclusions:

• Primary hyperoxalurias lead to severe kidney disease through oxalate overproduction and subsequent inflammation.
• The NLRP3 inflammasome plays a critical role in mediating the inflammatory response to calcium-oxalate crystals.
• Modulating the NLRP3 inflammasome presents a promising complementary therapeutic approach for primary hyperoxalurias and other crystalline nephropathies.